dibekacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, kanamycin and bekanamycin derivatives (obtained from Streptomyces kanamyceticus) | 855 | 34493-98-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.14 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 81 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.46 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.13 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.40 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1979 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01GB09 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Other aminoglycosides |
| ATC | S01AA29 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:33282 | bactericides |
| CHEBI has role | CHEBI:48001 | protein synthesis inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.15 | acidic |
| pKa2 | 13.85 | acidic |
| pKa3 | 8.7 | Basic |
| pKa4 | 7.75 | Basic |
| pKa5 | 7.15 | Basic |
| pKa6 | 6.81 | Basic |
| pKa7 | 5.55 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) | Enzyme | Km | 5.92 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| N0000168467 | NUI |
| D07811 | KEGG_DRUG |
| 3328 | RXNORM |
| C0012024 | UMLSCUI |
| CHEBI:37945 | CHEBI |
| 84D | PDB_CHEM_ID |
| CHEMBL560976 | ChEMBL_ID |
| D003982 | MESH_DESCRIPTOR_UI |
| DB13270 | DRUGBANK_ID |
| 12134 | IUPHAR_LIGAND_ID |
| 3610 | INN_ID |
| 45ZFO9E525 | UNII |
| 470999 | PUBCHEM_CID |
| 005321 | NDDF |
Pharmaceutical products:
None